Abstract 467P
Background
Surgical intervention is thought to increase the likelihood of subsequent dissemination in diffuse intrinsic pontine glioma (DIPG) patients. However, there is no study evaluating the factors influencing the timing of metastasis development. Hence, the present analysis was conducted to shed light on factors associated with subsequent dissemination timing.
Methods
This analysis included 28 pediatric (age≤12) DIPG cases with metastasis treated at Sanjiu Brain Hospital between June 1, 2017 and June 30, 2023. The clinical data were retrospectively collected following the initial diagnosis. The diagnosis was established by typical imaging features of DIPG. The same three radiologists analyzed the imaging data independently. Time to subsequent metastasis was estimated using Kaplan–Meier analysis, and a log-rank test evaluated the differences between groups.
Results
Of 28 patients, 13 (46.4%) were males and 15 were females. 23 (82.1%) underwent surgical intervention, while 5 (17.9%) did not receive surgery. The patients' median age was 7 years (2-12 yrs.). The Kaplan-Meier method showed that the median time to metastasis was 5.8 months (95%CI 4.2-9.1). The log-rank test demonstrated that adjuvant temozolomide was the only variable that could significantly delay metastasis in the pediatric DIPG population (P=0.03). The median time to metastasis from the day of initial diagnosis for those who received adjuvant temozolomide was 6.8 months (95%CI 5-10.7) vs. 3 months for those who did not receive adjuvant temozolomide (95%CI 2.3-NA). Sex, age, surgical intervention, and concurrent irradiation and temozolomide were not associated with metastasis timing.
Conclusions
Adjuvant temozolomide administration might benefit DIPG patients by delaying metastasis, especially in those who are at higher risk for subsequent metastasis, such as those who underwent surgical intervention. However, prospective studies are warranted to confirm these results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
489P - Interfering with the tumor microenvironment of glioblastoma: An in vitro study
Presenter: Serena Mastantuono
Session: Poster session 16
490P - Inhibiting glioma cells' migration: Exploring Rho-GTPases as a potential therapeutic target
Presenter: Irene Giulia Rolle
Session: Poster session 16
Resources:
Abstract
491P - SRSF7 promotes glioblastoma progression via CDK1-mediated G2/M phase arrest of GBM cells
Presenter: Ya qin Hu
Session: Poster session 16
Resources:
Abstract
492P - Linking cellular drug responses to corresponding metabolomic tissue signatures in gliomas
Presenter: Stefanie Stanzer
Session: Poster session 16
493P - The usefulness of pre-radiotherapy MRI in assessing pseudo-progression in patients with glioblastoma included in first-line clinical trials
Presenter: Kreina Vega Cano
Session: Poster session 16
494P - Effect of a new method for operating electric field patches on scalp reactions in glioblastoma patients receiving tumor treating fields
Presenter: Jinghui Liu
Session: Poster session 16
Resources:
Abstract
495P - Clinicopathological risk factors for prognosis and therapeutic response of primary central nervous system lymphoma in China: A single-center retrospective analysis of 118 cases
Presenter: Feng Chen
Session: Poster session 16
496P - Association of brain metastasis and peritumoral edema volume with the neurological symptom burden in lung cancer patients
Presenter: Ariane Steindl
Session: Poster session 16
497P - Does the primary location and metastatic timing of colorectal cancer influence the survival of patients with brain metastasis? A meta-analysis
Presenter: Junmin Song
Session: Poster session 16